康桕西普玻璃体腔内注射联合视网膜激光光凝对缺血型视网膜分支静脉阻塞继发黄斑水肿患者远期视力及预后影响  

Effect of Intravitreal Injection of Conbercept Combined with Retinal Laser Photocoagulation on Long-term Vision and Prognosis in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

作　　者：赵春燕 张海峰 张雪琴 王维为 ZHAO Chun-yan;ZHANG Hai-feng;ZHANG Xue-qin(Department of Ophthalmology,Beijing Huairou Hospital Affiliated to the University of Chinese Academy of Sciences,Beijing,101400,China)

机构地区：[1]北京怀柔医院眼科,北京101400

出　　处：《医学临床研究》2020年第2期210-212,共3页Journal of Clinical Research

摘　　要：【目的】探讨康柏西普玻璃体腔内注射联合视网膜激光光凝对缺血型视网膜分支静脉阻塞(BRVO)继发黄斑水肿患者远期视力及预后的影响。【方法】回顾性分析2016年10月至2017年6月在本院诊治的缺血型BRVO继发黄斑水肿患者45例(45眼),所有患者均采用康柏西普玻璃体腔注射联合视网膜激光光凝治疗,比较治疗前和治疗后1周、1个月、3个月、6个月、9个月及12个月患者黄斑中心视网膜厚度(CMT)、最佳矫正视力(BCVA)改变状况,并记录患者并发症与不良反应发生情况。【结果】患者治疗后1周、1个月、3个月、6个月、9个月及12个月时BCVA分别为0.44±0.07、0.45±0.05、0.52±0.07、0.54±0.06、0.62±0.05、0.90±0.10,均显著高于患者治疗前的0.39±0.07;治疗后1周、1个月、3个月、6个月、9个月及12个月时CMT分别是(295.14±63.51)mm、(275.39±60.14)mm、(249.63±61.50)mm、(238.75±62.55)mm、(232.64±64.71)mm、(210.08±60.09)mm,均显著低于治疗前的(679.24±62.31)mm,其差异均有统计学意义(P<0.05),治疗后不同时间点CMT比较差异均无统计学意义(P>0.05)。术后随访中患者未出现医源性白内障、高眼压、视网膜撕裂、玻璃体出血及眼内炎等眼部并发症。【结论】康柏西普联合视网膜激光光凝可显著提升缺血型BRVO继发黄斑水肿患者BCVA,降低CMT,且安全性高,值得临床推广应用。【Objective】To investigate the effect of intravitreal injection of Conbercept combined with retinal laser photocoagulation on the long-term vision and prognosis of patients with macular edema secondary to branch retinal vein occlusion(BRVO).【Methods】Retrospective analysis of 45 cases(45 eyes)of macular edema secondary to ischemia-type BRVO treated in our hospital from O ctober 2016 to June 2017 was performed,all patients were treated with Conbercept vitreous injection combined with retinal laser photocoagulation;and patients'macular center retinal thickness(CMT),best corrected visual acuity(BCVA)changes were com paredl week,1 month,3 months,6 months,9 months and 12 months pre-treatm ent and post-trea tment,and patient complications and adverse reactions were recorded.【Results】BCVA was 0.44±0.07,0.45±0.05,0.52±0.07,0.54±0.06,0.62±0.05,0.90±0.10 at 1 week,3 months,6 months,9 months and 12 months after treatment,respectively,which was significantly higher than 0.39±0.07 before treatment.CMT was(295.14±63.51)mm,(275.39±60.14)mm,(249.63±61.50)mm,(238.75±62.55)mm,(232.64±64.71)mm,(210.08±60.09)mm,respectively,significantly lower than(679.24±62.31)mm before treatment(P<0.05).There was no significant difference in CMT at different time points after treatment(P>0.05).There were no ocular complications such as iatrogenic cataract,high intraocular pressure,retinal tear,vitreous hemorrhage and end ophthalmitis.【Conclusion】Conbercept combined with retinal laser photocoagulation can significantly improve BCVA and reduce CMT in patients with macular edema secondary to BRVO,and it has high safety,which is worthy of clinical application.

关 键 词：视网膜静脉闭塞/治疗 激光凝固术 黄斑水肿/治疗 

分 类 号：R774.5[医药卫生—眼科]